Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 491 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Rebecca Taub sold 491 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total value of $212,082.54. Following the sale, the director directly owned 452,213 shares in the company, valued at $195,328,883.22. This trade represents a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Rebecca Taub also recently made the following trade(s):

• On Monday, January 26th, Rebecca Taub sold 647 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $492.42, for a total value of $318,595.74.
• On Tuesday, January 20th, Rebecca Taub sold 2,238 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $490.77, for a total value of $1,098,343.26.
• On Friday, January 9th, Rebecca Taub sold 18,410 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $522.40, for a total value of $9,617,384.00.
• On Friday, January 9th, Rebecca Taub sold 240 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $550.33, for a total value of $132,079.20.
• On Wednesday, December 10th, Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $552.15, for a total value of $10,297,597.50.

Madrigal Pharmaceuticals Stock Down 1.5%

Madrigal Pharmaceuticals stock traded down $6.51 during trading hours on Friday, reaching $432.83. The stock had a trading volume of 440,127 shares, compared to its average volume of 375,225. The company has a market cap of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The business’s 50 day moving average price is $492.64 and its 200-day moving average price is $486.72. Madrigal Pharmaceuticals, Inc. has a 52 week low of $265.00 and a 52 week high of $615.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The firm had revenue of $321.08 million during the quarter, compared to the consensus estimate of $310.36 million. During the same quarter in the prior year, the business posted ($2.71) earnings per share. The firm’s quarterly revenue was up 210.8% on a year-over-year basis. Sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MDGL. B. Riley Financial upped their price target on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Wolfe Research set a $579.00 target price on Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. UBS Group set a $900.00 price target on Madrigal Pharmaceuticals in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. Finally, HC Wainwright lifted their target price on shares of Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a “buy” rating in a research note on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $685.31.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Large investors have recently bought and sold shares of the company. Groupama Asset Managment raised its position in Madrigal Pharmaceuticals by 11.6% during the 4th quarter. Groupama Asset Managment now owns 30,620 shares of the biopharmaceutical company’s stock worth $17,831,000 after buying an additional 3,176 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Madrigal Pharmaceuticals during the fourth quarter worth $1,083,000. Invesco Ltd. lifted its position in Madrigal Pharmaceuticals by 21.9% during the fourth quarter. Invesco Ltd. now owns 365,314 shares of the biopharmaceutical company’s stock valued at $212,737,000 after purchasing an additional 65,749 shares during the period. EP Wealth Advisors LLC purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at $355,000. Finally, XTX Topco Ltd acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth about $1,642,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.